Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Biomarker testing detects actionable driver mutations to inform first-line treatment in advanced non-small-cell lung cancer (aNSCLC) and metastatic colorectal cancer (mCRC). This study evaluated biomarker testing in a nationwide database (NAT) versus the OneOncology (OneOnc) community network. Patients with aNSCLC or mCRC with ≥1 biomarker test in a de-identified electronic health record-derived database were evaluated. OneOnc oncologists were surveyed. Biomarker testing rates were high and comparable between OneOnc and NAT; next-generation sequencing (NGS) rates were higher at OneOnc. Patients with NGS versus other biomarker testing were more likely to receive targeted treatment. Operational challenges and insufficient tissue were barriers to NGS testing. Community cancer centers delivered personalized healthcare through biomarker testing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2022-1216 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of serum Ninj1 as a potential biomarker for predicting severity in patients with COVID-19.
Clin Chim Acta
September 2025
Department of Clinical Laboratory, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address:
Infection with SARS-CoV-2 elevates the expression of cytokines, resulting in a cytokine storm that serves as the primary factor for severe illness and mortality; however, effective markers for predicting disease severity and preventing are lacking. Thus, we investigated the association between serum levels of nerve injury-induced protein 1 (Ninj1), a mediator of plasma membrane rupture, and the extent of lung damage in COVID-19 patients was examined to anticipate the severity of SARS-CoV-2 infection. This study included 62 healthy participants and 264 patients with COVID-19.
View Article and Find Full Text PDFUCP2 is identified as a therapeutic target for abdominal aortic aneurysm by comprehensive bioinformatic analysis and experimental validation.
Biochem Biophys Res Commun
September 2025
Department of Vascular Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, China; Institute of Vascular Diseases, Central South University, Changsha, 410011, China. Electronic address:
Abdominal aortic aneurysm (AAA) is a potentially life-threatening vascular condition that currently lacks effective pharmacological treatment. The disease is strongly associated with chronic inflammation, where immune cells like macrophages play a crucial role. Efferocytosis, the process by which apoptotic cells are cleared, is involved in regulating inflammation.
View Article and Find Full Text PDFWastewater as a dual indicator of human and environmental exposure to synthetic antioxidants: Occurrence and fate in biological and advanced wastewater treatment.
Environ Int
August 2025
Eawag: Swiss Federal Institute of Aquatic Science and Technology, Ueberlandstrasse 133, 8600, Duebendorf, Switzerland; Institute of Biogeochemistry and Pollutant Dynamics, Universitaetstrasse 16, 8092, Zurich, Switzerland. Electronic address:
Synthetic antioxidants (SAOs) are widely used additives in industrial and consumer products, yet their human exposure and fate throughout wastewater treatment remain poorly understood. This study investigates the occurrence of SAOs and their human metabolites in wastewater influent as well as their abatement in three wastewater treatment plants (WWTPs) employing both conventional and advanced treatment technologies. In vitro human liver S9 assays were performed to generate a SAO metabolite MS2 library containing over 2500 potential metabolites, which was matched against wastewater influent data.
View Article and Find Full Text PDFInter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.
Mol Diagn Ther
September 2025
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.
View Article and Find Full Text PDFOld tests and new paradigms: How to interpret iron studies and related biomarkers for the diagnosis of iron deficiency in adults.
Blood Rev
August 2025
Department of Medicine, Stellenbosch University, Faculty of Medicine and Health Sciences, Tygerberg Campus, South Africa. Electronic address:
Clinicians need a good understanding of available tools to diagnose iron deficiency (ID). Interpretation of commonly used laboratory tests can be challenging due to the dynamic nature of iron homeostasis and concurrent inflammation, which influence results. The misinterpretation of iron studies, inconsistencies in ID diagnostic guidelines, and low awareness of non-anaemic ID may lead to missed diagnoses and opportunities for treatment.
View Article and Find Full Text PDF